

# The effects of vitamin D supplementation on indices of glycemic control in Iranian diabetics: A systematic review and meta-analysis

Reza Sahebi<sup>a,b</sup>, Majid Rezayi<sup>a,c,f</sup>, Maryam Emadzadeh<sup>e</sup>, Maryam Salehi<sup>e</sup>, Maryam Tayefi<sup>a,f</sup>,  
Seyed Mostafa Parizadeh<sup>f</sup>, Negin Behboodi<sup>a</sup>, Azam Rastgar-Moghadam<sup>a</sup>,  
Jasmin Kharazmi Khorassani<sup>g</sup>, Sara Kharazmi Khorassani<sup>h</sup>, Akbar Mohammadi<sup>i</sup>,  
Gordon A. Ferns<sup>j</sup>, Majid Ghayour Mobarhan<sup>d,f,\*</sup>

<sup>a</sup> Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>b</sup> Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

<sup>c</sup> Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>d</sup> Category 2 Institutes and Centers Under the Auspices of UNESCO, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>e</sup> Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>f</sup> Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>g</sup> Department of Chemistry, Ferdowsi University, Mashhad, Iran

<sup>h</sup> Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran

<sup>i</sup> Department of Clinical Biochemistry, Babol University of Medical Sciences, Babol, Iran

<sup>j</sup> Division of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, Sussex, BN1 9PH, UK

## ARTICLE INFO

### Keywords:

25(OH)D

Iran

Meta-analysis

Serum lipid profile

Type 2 diabetes

## ABSTRACT

**Background and purpose:** This systematic review and meta-analysis aimed to assess the effects of vitamin D supplements on indices of glycemic control [homeostatic model assessment-insulin resistance (HOMA-IR), hemoglobin A1C (HbA1C), fasting blood glucose (FBG), and quantitative insulin-sensitivity check index (QUICKI)] and lipid profile in diabetic patients.

**Methods:** Eight databases were searched, for randomized controlled trials (RCTs) or cross-sectional and cohort studies that have been published up to December 2017. We used the comprehensive meta-analysis (CMA) software for all statistical analysis and used the  $I^2$  index for assessing heterogeneity. A  $p$  value of  $< 0.05$  was considered as statistically significant.

**Results:** We found 621 articles, and after the exclusion of ineligible publications, 82 studies remained to be assessed of which 37 were used for meta-analysis. Vitamin D supplementation was associated with a significant improvement in FBG ( $p = 0.001$  and 95% CI:  $-0.526$  to  $-0.136$ ) and HbA1C ( $p = 0.003$  and 95% CI:  $1.719$  to  $-0.361$ ) in individuals with type 2 diabetes mellitus (T2DM); while in women with gestational diabetes mellitus (GDM) the reduction in FBG ( $p = 0.071$  and 95% CI:  $-0.873$  to  $-0.035$ ) and HbA1C ( $p = 0.199$  and 95% CI:  $3.270$  to  $0.681$ ) failed to reach statistical significance. Treatment with vitamin D supplements was associated with an improvement in HOMA-IR in pregnant diabetic women ( $p = 0.028$  and 95% CI:  $0.924$  to  $-0.053$ ) and for individuals with diabetes mellitus ( $p = 0.005$  and 95% CI:  $1.772$  to  $-0.319$ ). The pooled result of the cross-sectional meta-analysis indicated that serum vitamin D concentrations were significantly lower in diabetic patients than in healthy controls ( $p = 0.018$  and 95% CI:  $0.587$  to  $-0.054$ ).

**Conclusion:** This meta-analysis suggests that vitamin D supplementation improves indices of glycemic control (FBG, HOMA-IR, and HbA1C) in patients with diabetes mellitus. Hence, vitamin D supplements may be of potential therapeutic value in diabetic patients, as an adjuvant therapy along with other treatments.

## 1. Introduction

Diabetes mellitus, is one of the most common chronic metabolic

disorders and a significant global health concern [1]. Diabetes is characterized by hyperglycemia caused by insufficient secretion of insulin, insulin resistance, or both [2]. Deleterious long-term effects of

\* Corresponding author. Category 2 Institutes and Centers under the Auspices of UNESCO, Mashhad University of Medical Sciences, Mashhad, Iran.

E-mail address: [GhayourM@mums.ac.ir](mailto:GhayourM@mums.ac.ir) (M. Ghayour Mobarhan).

<https://doi.org/10.1016/j.ctcp.2018.12.009>

Received 15 July 2018; Received in revised form 15 December 2018; Accepted 16 December 2018

1744-3881/ © 2018 Elsevier Ltd. All rights reserved.

diabetes include macro- and micro-vascular disease, neuropathy, and nephropathy [3]. Furthermore, there is a relationship between diabetes and an increased risk of some cancers, that include: pancreatic, breast and colorectal cancers [4,5]. The International Diabetes Federation (IDF) has estimated that the number of people with diabetes is 425 million globally, of whom two-thirds live in industrial areas [6]. More than 60% of diabetic patients globally are located in Asia [7]. Approximately 4.5 million adult diabetic patients live in Iran and it is estimated 9.2 million people will be diabetic by 2030 [8]. There are three main categories of diabetes mellitus [2]:

- Type 1 diabetes mellitus (T1DM): T1DM or Insulin dependent diabetes mellitus (IDDM) is an autoimmune disease, in which pancreatic beta cells are targeted for destruction by T-cells [9], and in which genetic and environmental factors have an important role [10].
- Type2 diabetes mellitus (T2DM): T2DM is known as "non-insulin-dependent- diabetes mellitus" (NIDDM). This is the most common form of diabetes mellitus, and is associated with insulin resistance [11].
- Gestational diabetes mellitus (GDM): GDM is glucose intolerance, often associated with hyperlipidemia and insulin resistance [12,13] that arises in the second or third trimester of pregnancy, and can affect women without a past history of impaired glucose tolerance, and has a negative impact on fetal and neonatal well-being [11,14].

Vitamin D is a pro-hormone [15] that has an important role in insulin secretion [16], although its classical role is in the regulation of intestinal absorption of calcium, phosphate and their homeostasis [17]. Its sources include dermal synthesis following exposure to sunlight, from the diet (salmon, mackerel) and dietary fortification and supplements [18,19]. Vitamin D deficiency and insufficiency is now becoming a global health concern and affects over one billion children and adults [20,21]. Some studies have shown a high prevalence of vitamin D deficiency in tropical and sub-tropical countries that include: Iran, Turkey, China, India and, Saudi Arabia [22]. In Iran, approximately (3.9–6.6 million) people are affected with DM [6]. Vitamin D deficiency is associated with hypertension [23], cardiovascular disease [24], glucose intolerance, insulin resistance and increased risk of diabetes [25]. A serum 25-hydroxyvitamin D [25(OH)D] level of < 20 ng/ml is associated with increased risk of colon, prostate, and breast cancer [26,27]. There appears to be an inverse relationship between the risk of DM, its complications and, serum 25(OH) D levels [28,29]. Therefore, DM is more common in vitamin D deficient subjects and vitamin D may also have beneficial anti-inflammatory effects [31]. There have been trials of vitamin D supplementation in individuals with DM [30,31] although there has been no comprehensive evaluation of the association between vitamin D and DM. Therefore, we aimed to conduct this systematic and meta-analysis by pooling the results from clinical trials and cross-sectional studies to investigate the potential relationship between vitamin D and DM.

## 2. Method

### 2.1. Search of literature

Relevant articles were identified using PubMed, Scopus, Web of Science, Cochrane Library, Google Scholar, ScienceDirect, Scientific Information Database (SID) and IranMedex up to December 2017. The search terms used were the following combination of keywords: ("vitamin D" or Vit D "25(OH)D") AND (diabetes or DM or diabetic) AND Iran [MeSH Terms] OR ("vitamin D" or "25(OH)D") AND (diabetes or DM or diabetic) AND Iran [All Fields], and Persian keywords in the title, abstract, and keywords. Initially, we evaluated all original articles in both English and Persian language including cross-sectional studies, cohort and randomized controlled trials that assessed the correlation

and effect of vitamin D with or on DM, with no limitation for date. In the case of RCTs, we included all clinical trials with vitamin D (in forms of supplement or enriched in food) as the intervention and calcium, or placebo, as a control. The outcomes of interest in these studies were: fasting blood glucose (FBG), HbA1C and homeostatic model assessment-insulin resistance (HOMA-IR). Cell-line, animal experiments, review articles, laboratory studies, irrelevant topics, duplicate publication, non-clinical trials, and case reports were excluded. Other exclusion criteria included: incomplete data sets, the difference in baseline characteristics of all outcomes of interest, or lacking data about their similarity at baseline (in RCTs), book chapters, an absence of relevant data, lack of accurate data needed for our analysis. The quality appraisal for each article was performed according to particular criteria outlined by Joanna Briggs for cross-sectional studies and RCTs [32]. Studies with high scores (> 50%) were considered to be high quality.

### 2.2. Data extraction

Data extracted included: the last name of the first author and publication year, location and type of study, sample size with the drop-out rate of population if available, population characteristics (number, age, sex), serum vitamin D concentration, dose, and duration of intervention 25(OH)D, assessment of further outcomes and limitation of the study were noted. In some studies, for which relevant data were missing, contact was made with the principal authors for more information. All the articles included were independently assessed by two reviewers (MR and RS) who read the full-text of the papers, and a consensus was reached in case of any inconsistency with the involvement of a third author (M. E).

### 2.3. Statistical analysis

Comprehensive meta-analysis (CMA) software was used for all statistical analysis. The  $I^2$  index was used to assess heterogeneity, and in case of heterogeneity ( $I^2$  value > 50%). A  $P < 0.05$  was considered statistically significant.

### 2.4. Search results and study characteristics

Fig. 1 shows the study selection data. We identified 621 articles using a systematic search, of which 53 studies were excluded because of duplication. From the remaining 568 studies, 463 publications were excluded because they were review articles, laboratory studies, irrelevant topics, duplicate publication, or non-clinical studies. The remaining 105 papers were evaluated for eligibility by examining their full text and 23 studies excluded because of incomplete data, or because they were book chapters, or animal studies. Finally, 82 articles remained to be assessed. There were 52 RCTs, 29 cross-sectional and one cohort study. These 82 studies were analyzed based on the quality measurement scale and inclusion and exclusion criteria. Although 82 studies were found to be appropriate for systematic analysis, 45 studies were excluded because the groups were not matched and differed significantly for glycemic indices at baseline. Some studies investigated gene polymorphisms, and did not document glycemic indices. A total of 37 articles were used for meta-analysis. In all, 11614 and 1673 individuals were included in the systematic review and meta-analysis, respectively.

#### 2.4.1. The relation between serum vitamin D and measures of diabetes mellitus

Table 1 shows the results of RCTs on the effects of vitamin D supplementation or vitamin D fortified food versus placebo, calcium or non-fortified food. The data indicate that vitamin D supplementation significantly reduced HOMA-IR, HbA1C, fasting blood glucose (FBG), and high-sensitivity C-Reactive Protein (hs-CRP). Vitamin D




Fig. 1. Flow chart of literature search and study selection.

supplementation was associated with an improvement in lipid profile and insulin sensitivity by Quantitative Insulin-Sensitivity Check Index. The data for the cross-sectional and cohort studies are shown in Table 2. Unsurprisingly, FBG, HbA1C, and HOMA-IR were higher in the diabetic patient compared to healthy subjects, and serum vitamin D was lower in diabetics than in healthy controls.

### 3. Results

Fig. 3 shows the results of the meta-analysis for RCTs for FBG. The overall pooled results for the effects of vitamin D supplementation on FBG in GDM were not significant ( $p = 0.071$ , and 95% CI:  $-0.873$  to  $0.035$ ) for GDM, but were significant in T2DM ( $p = 0.001$ , and 95% CI:  $-0.526$  to  $-0.136$ ). Although the relative weight of the study of Valizadeh et al. on GDM patients was higher than other studies, the result of this study was also non-significant ( $p = 0.119$ ). Furthermore, the results of the sensitivity analysis showed that following the elimination of the study of Valizadeh et al. the final results were significant. Perhaps the high-dose vitamin D consumption and short-term follow up in Valizadeh's study in comparison with other studies may have been the cause of the lack of a significant result. Overall, vitamin D supplementation was associated with a significant improvement in FBG in diabetic patients (Fig. 3a and b).

Fig. 4 shows that vitamin D supplements had no significant effect on HbA1C in GDM ( $p = 0.199$  and 95% CI:  $3.270$  to  $0.681$ ), but there was a significant effect on HbA1C in T2DM ( $p = 0.003$  and 95% CI:  $1.719$  to

$-0.361$ ). However, only the intervention study of Yazdchi in pregnant diabetic patients revealed significant effects, which may be due to factors such as the assessment of dietary intakes, use of matched categories regarding known confounders, sunlight exposure and pre-pregnancy BMI. Overall the final result was significantly in favor of intervention. This means that the intervention leads to a significant reduction in HbA1C in T2DM.

In Fig. 5, the study by Yazdchi et al. reported that vitamin D was not associated with an improvement in HOMA-IR, but overall, after increasing vitamin D intake, this did improve significantly ( $p = 0.028$  and 95% CI:  $0.924$  to  $-0.053$ ) in pregnant diabetic women. Also, vitamin D supplements were associated with a significant improvement in HOMA-IR ( $p = 0.005$  and 95% CI:  $1.772$  to  $-0.319$ ) in DM patients (Tables S1–S6).

In Fig. 6 the overall pooled result of cross-sectional meta-analysis indicated vitamin D level was lower ( $p = 0.018$  and 95% CI:  $0.587$  to  $-0.054$ ) in diabetic patients than for healthy controls (Table S7).

### 4. Discussion

We have undertaken a systematic review of the effects of dietary vitamin D on lipid profile, glycemic control and insulin resistance index in diabetic patients, that included GDM, T1DM, and T2DM. GDM affects approximately 4.7% of pregnant women in Iran [106]. Various factors, such as vitamin D deficiency and fast food intake are suggested as a risk factor for GDM [107,108]. In our systematic review, we found that




Fig. 2. The reported effects of vitamin D supplement in diabetics.

fasting plasma glucose (FPG) [80,83], HbA1C [81] and HOMA-IR were significantly higher in women with GDM, whereas serum insulin [81] and vitamin D levels [80] were lower compared with healthy control. Furthermore, vitamin D supplementation was associated with a significant reduction in HOMA-IR [36], FPG [44] and insulin [36] and an increase in QUICKI and sensitivity to insulin in the intervention group [40]. In agreement with previous studies, Shahgheibi et al. demonstrated, vitamin D supplementation intake has potentially beneficial effects as assessed by an improvement in glucose tolerance test (GTT) and reduction in the prevalence of GDM [39]. In a cohort study in Tehran, GDM subjects with postpartum metabolic syndrome had higher fasting glucose, and lower serum parathyroid hormone (PTH) than healthy control [84]. In some studies, vitamin D supplementation did not affect FPG [43], or insulin resistance [43] and there was no significant relationship between GDM with serum vitamin D levels [80,83]. Overall vitamin D consumption in women with GDM improved measures of glycemic status [36] and HbA1C levels and no complications have been reported [44]. Vitamin D plays a potentially important role in T1DM by suppressing activation of T-cells [97]. Although Ghandchi and co-workers report that FSG and HbA1C were higher in patients with T1DM compared to healthy control, serum vitamin D did not differ significantly between the subjects and unrelated non-diabetic controls. It has been proposed that vitamin D consumption in those who are genetically predisposed to the disease (i.e., siblings) may prevent T1DM [99]. Consumption of vitamin D supplements have a beneficial effect on HbA1C [48] and FBG in patients with T1DM and vitamin D insufficiency [46]. Ataie-Jafari et al. found that children with T1DM who are exposed to sunlight  $\geq 15$  min at weekends have a lower prevalence of vitamin D deficiency than T1DM children with  $< 15$  min

exposure to sunlight. Because exposure to sunlight is an important source of vitamin D and also according to Ghandchi et al., vitamin D levels are important to the T helper 1 and T helper 2 balance and susceptibility to T1DM [47]. Saki et al. observed the prevalence of vitamin D deficiency in boys with T1DM was lower than for girls [85]. Finally, we suggest that vitamin D supplementation could be an auxiliary treatment in patients with T1DM. According to the 8th International Diabetes Federation (IDF), the prevalence of T2DM in Iran is in excess of 4 million (8.43%) [109]. A low serum 25-hydroxy vitamin D [25(OH)D] has been associated with impaired glucose tolerance in T2DM [52]. The concentration of serum vitamin D is reported to be lower in diabetic patients than in healthy people [23,87,90,104,105]. Esteghamati et al. showed that vitamin D deficiency is associated with reduced insulin-producing in T2DM [101]. RCTs indicate that vitamin D supplements can improve serum vitamin D level [55], glycemic indicator [49,53,55,65,78], serum hs-CRP [53,68,69], lipid profile and HOMA-IR [49,55,60,72]. Furthermore, several studies have shown that HbA1C is reduced in intervention group compared to control group [53,60,64,72,110,111]. However, in some studies HbA1C was reduced in both groups. It is possible that the improvement in the control group was due to dietary change and taking plain dough that contains calcium without vitamin D [61,112,113]. In contrast to these studies, Eftekhari and Jafari showed that HbA1C was increased in the intervention and control group [114,115] and in similarly Ahmadi et al. indicated HbA1C is increased in intervention group only. Moreover vitamin D supplementation for three months had no significant effect on reducing proteinuria in diabetic patients [70]. Some studies have demonstrated that dietary vitamin D intake reduces insulin in the intervention group [51,60,68,72,111,115–117]. Furthermore, Heshmat demonstrated the

**Table 1**

RCTs for the effects of vitamin D supplementation or vitamin D fortified food versus placebo, calcium or non-fortified food [25,31,33–79].

| Ref.            | City/<br>Sample<br>size (n) | Type of<br>diabetes | Serum Vitamin D<br>assessment*<br>(ng/ml) |                 | Significant<br>outcome                                                                                                     | Non significant<br>outcome                                              |
|-----------------|-----------------------------|---------------------|-------------------------------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                 |                             |                     | Before                                    | After           |                                                                                                                            |                                                                         |
| [33–35]         | Arak/260                    | GDM                 | 15.2 ± 3.8                                | 30.4 ± 4.1      | FPG/ Insulin/ HOMA-IR<br>HOMA-β / LDL<br>cholesterol<br>↓                                                                  | Serum Ca level<br>↑<br>HOMA-IR/ HOMA-β<br>TC/TAG<br>↓                   |
| [36–38]         | Kashan/155                  | GDM                 | 17                                        | 30              | FPG/ Serum insulin<br>HOMA-IR<br>↓                                                                                         | Insulin resistance<br>LDL/ TC<br>hs-CRP<br>↓                            |
| [39]            | Sanandaj/90                 | GDM                 | 13.5                                      | Not<br>reported | GCT/ GTT<br>↓                                                                                                              | Not reported                                                            |
| [40–42]         | Yazd/560                    | GDM                 | 21.1                                      | 52              | FBG/ 1-h OGTT / PTH<br>↓                                                                                                   | QUICKI<br>Insulin sensitivity<br>HbA1C<br>↑<br>FPG<br>↓                 |
| [43]            | Zanjan/84                   | GDM                 | 14.6                                      | 32.4            | Not reported                                                                                                               | HbA1C/ HOMA-IR<br>↑                                                     |
| [44]            | Tabriz/72                   | GDM                 | 6.12±15.9<br>4                            | 24.70±<br>37.94 | FBG/ HbA1C<br>↓                                                                                                            | Not reported                                                            |
| [45]            | Isfahan/210                 | GDM                 | Not reported                              |                 | Not reported                                                                                                               | Vitamin<br>D cannot prevent the<br>incidence of<br>gestational diabetes |
| [46]            | Gorgan/47                   | T1DM                | Not reported                              |                 | HbA1C<br>↓                                                                                                                 | Not reported                                                            |
| [47]            | Tehran/53                   | T1DM                | 14                                        | Not<br>reported | Not reported                                                                                                               | Vitamin D deficiency<br>in boys was lower than<br>girls in this model   |
| [48]            | Yazd/65                     | T1DM                | Not reported                              |                 | FBG/ HbA1C<br>↓                                                                                                            | Not reported                                                            |
| [49]            | Arak/100                    | T2DM                | 43.03±19.2<br>8                           | 60.12±17.2      | Not reported                                                                                                               | 1. Insulin<br>2. HOMA-IR<br>3. Serum FPG<br>↓                           |
| [25, 50–<br>63] | Tehran/1585                 | T2DM                | 33.69                                     | 49.84           | Insulin/ TG/ TC/ MMP-9<br>FSG/ HbA1C / hs-CRP<br>HOMA-IR/ IL-1/ IL-6<br>Fibrinogen / TNF-α<br>↓<br>Apo A1/ Apo B/ GSH<br>↑ | QUICKI/ MDA/<br>Cardiac<br>myeloperoxidase(MP)/<br>SOD<br>↓             |
| [64]            | Urmia/51                    | T2DM                | 21.46±4.6<br>5                            | 46.39±6.8<br>9  | TNF-α/ HbA1C<br>↓                                                                                                          | Serum leptin<br>↑<br>LDL/ HDL/ TC/ TG<br>FBG<br>↓                       |
| [65, 66]        | Shiraz/140                  | T2DM                | 43.3±32.1                                 | 34.1±31.5       | Not reported                                                                                                               | Level of insulin<br>↑<br>Not reported                                   |
| [67]            | Qom/120                     | T2DM                | Not reported                              |                 | HOMA-IR<br>↓                                                                                                               | Not reported                                                            |
| [68, 69]        | Kashan/126                  | T2DM                | 16                                        | 28              | Insulin/ HOMA-IR/<br>HOMA-β / hs-CRP<br>↓                                                                                  | FPG<br>↓<br>HbA1C/ GFR/ Serum<br>Ca/P<br>↑                              |
| [31, 70–<br>75] | Isfahan/595                 | T2DM                | 15.23                                     | 38.27           | SBP/ HbA1C/ Serum<br>insulin/ HOMA-IR<br>LDL-cholesterol/ HOMA-<br>β / IL-6/ TNF-α<br>↓                                    | BUN/ Serum Cr/<br>UACR/ FSG<br>↓                                        |
| [76]            | Yazd/53                     | T2DM                | 19                                        | 69              | Insulin/ Insulin resistance<br>↓                                                                                           | FBG<br>↓                                                                |
| [77–79]         | Shahrekord/<br>180          | T2DM                | 18                                        | 35              | SBP/ DBP<br>↓                                                                                                              | Proteinuria/ HbA1C<br>↓<br>FBG<br>↑                                     |


\*The mean concentration of vitamin D (before and after intervention) is shown in the study for each city; GDM: gestational diabetes mellitus; HbA1C: hemoglobin A1C; T1DM: Type 1 diabetes mellitus; HOMA- $\beta$ : Homeostatic Model Assessment  $\beta$ -cell function; T2DM: Type 2 diabetes mellitus; FPG: fasting plasma glucose; HOMA-IR: Homeostatic Model Assessment Insulin Resistance; LDL: low-density lipoprotein; Ca: Calcium; Cr: Chromium; TC: total cholesterol; TAG: triacylglyceride; FBG: fasting blood glucose; hs-CRP: high-sensitivity C-Reactive Protein; GCT: Glucose Challenge Test; GTT: Glucose Tolerance Test; 1-h OGTT: 1 h oral glucose tolerance test; PTH: Parathyroid Hormone; QUICKI: Quantitative Insulin-Sensitivity Check Index; MMP-9: matrix metalloproteinase 9; FSG: fasting serum glucose; TNF- $\alpha$ : tumor necrosis factor alpha; MDA: Malondialdehyde; SOD: superoxide dismutase; GSH: Glutathione; APO: Apolipoprotein; IL: Interleukin; HDL: High-Density Lipoprotein; GFR: glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; BUN: blood urea nitrogen; P: phosphate; UACR: urine albumin/creatinine ratio;  $\uparrow$ : Increased level;  $\downarrow$ : decreased level.

**Table 2**

The cross-sectional and Cohort studies for the effects of vitamin D supplementation or vitamin D fortified food versus placebo, calcium or non-fortified food [23,80–105].

| Reference   | City/<br>Sample size | Type of<br>diabetes | Significant outcome                                                                                                                                                                                                                                                                 | Non significant outcome                                                                           |
|-------------|----------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| [80]        | Yazd/204             | GDM                 | Not reported                                                                                                                                                                                                                                                                        | FSG<br>$\uparrow$                                                                                 |
| [81]        | Shahrekord/155       | GDM                 | Insulin<br>$\downarrow$                                                                                                                                                                                                                                                             | FBG/ HbA1C<br>$\uparrow$                                                                          |
| [82]        | Ahvaz/90             | GDM                 | Not reported                                                                                                                                                                                                                                                                        | Fasting blood Insulin/ TNF- $\alpha$<br>hs-CRP/ HOMA-IR/ FBG<br>$\uparrow$                        |
| [83]        | Tabriz/136           | GDM                 | FBG/ GTT 1h/ GTT 2h<br>$\uparrow$                                                                                                                                                                                                                                                   | Not reported                                                                                      |
| [84]        | Tehran/303           | GDM                 | Fasting glucose<br>$\uparrow$                                                                                                                                                                                                                                                       | Fasting insulin/ C-peptide/ ff genotype<br>$\uparrow$ PTH<br>$\downarrow$                         |
| [85]        | Shiraz/85            | T1DM                | Not reported                                                                                                                                                                                                                                                                        | FBG/ HbA1C/ Ca<br>$\uparrow$                                                                      |
| [23, 86-89] | Tehran/776           | T2DM                | FBG/ TG<br>$\downarrow$                                                                                                                                                                                                                                                             | Insulin/ PTH/ HbA1C<br>Serum P/ Serum Ca<br>$\downarrow$                                          |
|             |                      |                     | HbA1C/ HOMA-IR/ FBG<br>$\uparrow$                                                                                                                                                                                                                                                   | PTH<br>$\uparrow$                                                                                 |
| [90-92]     | Mashhad/473          | T2DM                | hs-CRP/ GFR<br>$\downarrow$                                                                                                                                                                                                                                                         | FBG/ HbA1C/ TG/ Insulin<br>$\downarrow$                                                           |
| [93]        | Ahvaz/84             | T2DM                | HbA1C/ hs-CRP<br>$\uparrow$                                                                                                                                                                                                                                                         | TNF- $\alpha$ / FBG<br>$\uparrow$                                                                 |
| [94]        | Zanjan/375           | T2DM                | Not reported                                                                                                                                                                                                                                                                        | Insulin/ HOMA-IR/ LDL<br>$\uparrow$                                                               |
| [95]        | Shahrekord/36        | T2DM                | 25-hydroxyvitamin D level in<br>none-diabetic<br>$\downarrow$                                                                                                                                                                                                                       | FPG<br>$\downarrow$                                                                               |
|             |                      |                     | FBG/ 1hPPG/ 2hPPG<br>$\uparrow$                                                                                                                                                                                                                                                     | Not reported                                                                                      |
| [96]        | Arak/314             | GDM                 | Not reported                                                                                                                                                                                                                                                                        | The CC genotype of VDR Apal<br>polymorphism increased the risk of<br>GDM                          |
| [97, 98]    | Mashhad/301          | T1DM                | Not reported                                                                                                                                                                                                                                                                        | frequencies<br>of 3 genotypes (Aa, FF, and Bb)<br>$\uparrow$                                      |
| [99]        | Tehran/180           | T1DM                | FSG and HbA1C<br>$\uparrow$                                                                                                                                                                                                                                                         | Not reported                                                                                      |
| [100-102]   | Tehran/3016          | T2DM                | SBP<br>$\uparrow$                                                                                                                                                                                                                                                                   | DBP/ FPG/ HbA1C<br>HOMA-IR<br>$\uparrow$                                                          |
|             |                      |                     | Tt genotype of the VDR Gene<br>presented a significantly higher<br>FBG than those with TT and tt<br>genotypes in TaqI polymorphisms<br>The frequency of Polymorphisms<br>Within Intron 8 and Exon 9 of the<br>VDR Gene in T2D Patients<br>compared with HC:<br>Tt/ Aa<br>$\uparrow$ | HOMA- $\beta$<br>$\downarrow$                                                                     |
| [103]       | Rafsanjan/200        | T2DM                | Not reported                                                                                                                                                                                                                                                                        | Not reported                                                                                      |
| [104]       | Babol/240            | T2DM                | Not reported                                                                                                                                                                                                                                                                        | The mean concentration of vitamin D<br>in women with diabetes was lower than<br>the healthy women |
| [105]       | Zahedan/100          | T2DM                | Not reported                                                                                                                                                                                                                                                                        | BMI<br>$\downarrow$                                                                               |

GDM: gestational diabetes mellitus; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; FPG: fasting plasma glucose; DBP: diastolic blood pressure; HbA1C: hemoglobin A1C; HOMA-IR: Homeostatic Model Assessment Insulin Resistance; Ca: Calcium; hs-CRP: high-sensitivity C-Reactive Protein; LDL: Low-Density Lipoprotein; GTT: Glucose Tolerance Test; FBG: Fasting blood glucose; PTH: parathyroid hormone; FSG: fasting serum glucose; TNF- $\alpha$ : Tumor Necrosis Factor-alpha; VDR: vitamin D receptor; APO: apolipoprotein; SBP: systolic blood pressure; P: phosphate; PPG: post prandial glucose; HOMA- $\beta$ : Homeostatic Model Assessment  $\beta$ -cell function; BMI: body mass index; GFR: glomerular filtration rate; HC: Healthy control;  $\uparrow$ : Increased level;  $\downarrow$ : decreased level.




GDM: gestational diabetes mellitus; T2DM: Type 2 diabetes mellitus; FBG: fasting blood glucose; RCTs: randomized controlled trials; CI: confidence interval; Std diff in means: standard difference in means.

**Fig. 3.** Forest plots of the association between intake of vitamin D and FBG in RCTs (a) GDM and (b) T2DM studies. The centre of each square indicates the horizontal line indicates the 95% CI; the area of the square is proportional to the amount of information from that study; diamonds are pooled estimates.

consumption of vitamin D plus calcium is more effective compared with intake vitamin D only to decrease the risk of T2DM [51]. Following some previous studies, Mohammadi showed that vitamin D supplementation leads to a significant reduction to insulin resistance in the

intervention group [76]. In some studies, calcium plus vitamin D supplements have been shown to have a positive effect on BMI, hip circumference and systolic blood pressure in subjects with T2DM [71,72]. Hoseini et al. observed that the intake of vitamin D supplements did not



GDM: gestational diabetes mellitus; T2DM: Type 2 diabetes mellitus; HbA1C: hemoglobin A1C; RCTs: randomized controlled trials; CI: confidence interval; Std diff in means: standard difference in means.

**Fig. 4.** Forest plots of the association between intake of vitamin D and HbA1C in RCTs (a) GDM and (b) T2DM diabetes studies.




Fig. 5. Forest plots of the association between intake of vitamin D and HOMA-IR in RCTs (a) GDM and (b) DM diabetes studies.

effect on insulin sensitivity, however it caused a reduction in FPG and HbA1C, that was increased in pre-diabetic subjects [118].

4.1. Vitamin D fortification studies

The main source of vitamin D in humans is from synthesis in the skin. Factors such as the duration of exposure, latitude, season, senescence, skin pigmentation and the continued use of sunscreens can affect the synthesis of vitamin D [119]. Although fortification of foods with vitamin D is not usual in Iran, some research has led to the proposal that the daily intake of a vitamin D should be increased by fortified yogurt drink, either with or without added calcium, improved glycemic status in T2DM patients [31,52,120]. Nikooyeh and Shab-bidar showed, serum glucose, HbA1C, HOMA-IR, oxidative stress (OS) [85,86] and insulin improved after vitamin D-fortified yogurt drink and vitamin D plus calcium-fortified yogurt drink intake in the intervention group [52]. Furthermore, Hajmohammadi et al. have suggested vitamin D3-

fortified doogh compared with plain doogh leads to a reduction in serum hs-CRP and parathyroid hormone (PTH) concentrations [58].

4.2. Vitamin D and diabetic neuropathy

Diabetic neuropathy (DN) is the most common complication of DM and also a major cause of morbidity and mortality in diabetic patients. Alamdari et al. in a cross-sectional study, observed reduction the levels of circulating 25(OH)-D was associated with an increased risk of large fiber neuropathy and FBG in type2 diabetic people [121]. In other research, Esteghamati et al. suggested an intake of vitamin D should be done more carefully, particular in diabetic subjects. As well as results showed FPG and HbA1C were increased in DN [122].

4.3. Vitamin D & diabetic foot ulcer

Diabetic foot ulcer (DFU) is known as one serious vascular




Fig. 6. Forest plot of the comparison between vitamin D level in Diabetic patients and Healthy control.

complications of diabetes. Razzaghi indicated, in diabetic patients with foot ulcer, vitamin D supplementation intake caused to improve glucose homeostasis, lipid profiles, decreases HbA1C and FPG. They suggested, improve glucose homeostasis had indirectly beneficial effects on wound healing [123]. Pooled data from all studies suggested, intake vitamin D supplement and vitamin D3-fortified doogh/yogurt improve several factors in diabetic patients after intervention. In Fig. 2, some of the effects of vitamin D on diabetics have been shown.

#### 4.4. Strengths and limitations

This review is the first meta-analysis assessing the effect of vitamin D on glycemic indices in diverse subgroups of diabetes and also, summarizes cross-sectional, cohort and interventional studies in diabetic patients. However, it should be noted that a major limitation of our study is the lack of pre and post-baseline measures for glycaemic indices in several papers, requiring them to be excluded from the meta-analysis.

#### 5. Conclusion

This systematic and meta-analysis review demonstrated that vitamin D had major effects on FBG of type 2 diabetics and pregnant women with diabetes. Therefore, vitamin D could be used as an adjuvant therapy along with the other treatments for those patients. Also, vitamin D supplementation leads to an improvement in HOMA-IR, FBG, and HbA1C. Furthermore, the overall pooled result of the cross-sectional meta-analysis showed the level of vitamin D is lower in diabetic patients than healthy control significantly. However, further studies are required to better understand the relationship between vitamin D supplementation and glucose homeostasis indexes in type 2 diabetes patients and pregnant diabetic women.

#### Conflicts of interest

The authors disclose no conflicts of interest.

#### Acknowledgment

This work were supported by World Health Organization office in Tehran, Iran and Mashhad University of Medical Sciences, Mashhad, Iran.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ctcp.2018.12.009>.

#### References

- [1] N. Abirami, R. Arulmozhi, In-silico approach towards protein targets related to diabetes mellitus-an overview, *Orient. J. Chem.* 33 (4) (2017) 1614–1622.
- [2] A.D. Association, Diagnosis and classification of diabetes mellitus, *Diabetes Care* 37 (Supplement 1) (2014) S81–S90.
- [3] B.K. Tripathi, A.K. Srivastava, Diabetes mellitus: complications and therapeutics, *Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.* 12 (7) (2006) RA130–RA147.
- [4] S.C. Larsson, N. Orsini, A. Wolk, Diabetes mellitus and risk of colorectal cancer: a meta-analysis, *J. Natl. Cancer Inst.* 97 (22) (2005) 1679–1687.
- [5] S.C. Larsson, C.S. Mantzoros, A. Wolk, Diabetes mellitus and risk of breast cancer: a meta-analysis, *Int. J. Canc.* 121 (4) (2007) 856–862.
- [6] IDF DIABETES ATLAS, eighth ed., (2017).
- [7] A. Ramachandran, C. Snehalatha, A.S. Shetty, A. Nanditha, Trends in prevalence of diabetes in Asian countries, *World J. Diabetes* 3 (6) (2012) 110.
- [8] A. Esteghamati, B. Larijani, M.H. Aghajani, F. Ghaemi, J. Kermanchi, A. Shahrami, M. Saadat, E.N. Esfahani, M. Ganji, S. Noshad, Diabetes in Iran: prospective analysis from first nationwide diabetes report of national program for prevention and control of diabetes (NPPCD-2016), *Sci. Rep.* 7 (2017).
- [9] M.A. Atkinson, N.K. Maclaren, The pathogenesis of insulin-dependent diabetes mellitus, *N. Engl. J. Med.* 331 (21) (1994) 1428–1436.
- [10] J.A. Todd, From genome to aetiology in a multifactorial disease, type 1 diabetes, *Bioessays* 21 (2) (1999) 164–174.
- [11] A.D. Association, 2. Classification and diagnosis of diabetes, *Diabetes Care* 40 (Supplement 1) (2017) S11–S24.
- [12] M.C. Serra, A.S. Ryan, Influence of Vitamin D and Parathyroid Hormone on Bone and Metabolic Risk in Women with Previous Gestational Diabetes, *Hormone and Metabolic Research*, (2016).
- [13] I. Prevention, Standards of medical care in diabetes—2011, *Diabetes Care* 34 (2011) S11.
- [14] D. Jaskolka, R. Retnakaran, B. Zinman, C.K. Kramer, Sex of the Baby and Risk of Gestational Diabetes Mellitus in the Mother: a Systematic Review and Meta-analysis, *Springer*, 2015.
- [15] P. Autier, M. Boniol, C. Pizot, P. Mullie, Vitamin D status and ill health: a systematic review, *Lancet Diabet. Endocrinol.* 2 (1) (2014) 76–89.
- [16] X. Palomer, J. González-Clemente, F. Blanco-Vaca, D. Mauricio, Role of vitamin D in the pathogenesis of type 2 diabetes mellitus, *Diabetes Obes. Metab.* 10 (3) (2008) 185–197.
- [17] D.D. Bikle, Vitamin D metabolism, mechanism of action, and clinical applications, *Chem. Biol.* 21 (3) (2014) 319–329.
- [18] D. Prié, L. Beck, G. Friedlander, C. Silve, Sodium-phosphate cotransporters, nephrolithiasis and bone demineralization, *Curr. Opin. Nephrol. Hypertens.* 13 (6) (2004) 675–681.
- [19] D. Prié, L. Beck, P. Urena, G. Friedlander, Recent findings in phosphate homeostasis, *Curr. Opin. Nephrol. Hypertens.* 14 (4) (2005) 318–324.
- [20] M.F. Holick, The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention, *Rev. Endocr. Metab. Disord.* (2017) 1–13.
- [21] R. Tabrizi, M. Moosazadeh, M. Akbari, M.H. Dabbaghmanesh, M. Mohamadkhani, Z. Asemi, S.T. Heydari, M. Akbari, K.B. Lankarani, High prevalence of vitamin D deficiency among the Iranian population: a systematic review and meta-analysis, *Iranian Journal of Medical Sciences*, 2017.
- [22] R. Heshmat, et al., Vitamin D Deficiency in Iran: a Multi-center Study Among Different Urban Areas Iranian, *J. Publ Health*, 2008.
- [23] E. Taheri, A. Saedisomeolia, M. Djalali, M. Qorbani, M.M. Civi, The relationship between serum 25-hydroxy vitamin D concentration and obesity in type 2 diabetic patients and healthy subjects, *J. Diabetes Metab. Disord.* 11 (1) (2012) 16.
- [24] P. Anagnostis, V.G. Athyros, F. Adamidou, M. Florentin, A. Karagiannis, Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? *Curr. Vasc. Pharmacol.* 8 (5) (2010) 720–730.
- [25] T.R. Neyestani, A. Djazayeri, S. Shab-Bidar, M.R. Eshraghian, A. Kalayi, N. Shariatzadeh, N. Khalaji, M. Zahedirad, A. Houshiarad, M. Chamari, Vitamin D receptor fok-I polymorphism modulates diabetic host response to vitamin D intake, *Diabetes Care* 36 (3) (2013) 550–556.
- [26] E.D. Gorham, C.F. Garland, F.C. Garland, W.B. Grant, S.B. Mohr, M. Lipkin, H.L. Newmark, E. Giovannucci, M. Wei, M.F. Holick, Vitamin D and prevention of colorectal cancer, *J. Steroid Biochem. Mol. Biol.* 97 (1) (2005) 179–194.
- [27] C.F. Garland, F.C. Garland, E.D. Gorham, M. Lipkin, H. Newmark, S.B. Mohr, M.F. Holick, The role of vitamin D in cancer prevention, *Am. J. Public Health* 96 (2) (2006) 252–261.
- [28] H. Derakhshanian, S. Shab-Bidar, J.R. Speakman, H. Nadimi, K. Djafarian, Vitamin D and diabetic nephropathy: a systematic review and meta-analysis, *Nutrition* 31 (10) (2015) 1189–1194.
- [29] D. Teegarden, S.S. Donkin, Vitamin D: emerging new roles in insulin sensitivity, *Nutr. Res. Rev.* 22 (1) (2009) 82–92.
- [30] T. Jafari, A.A. Fallah, A. Barani, Effects of vitamin D on serum lipid profile in patients with type 2 diabetes: a meta-analysis of randomized controlled trials, *Clin. Nutr.* 35 (6) (2016) 1259–1268.
- [31] T. Jafari, E. Faghihimani, A. Feizi, B. Iraj, S.H. Javanmard, A. Esmailzadeh, A.A. Fallah, G. Askari, Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: a randomised controlled clinical trial, *Clin. Nutr.* 35 (1) (2016) 67–76.
- [32] <http://joannabriggs.org/research/critical-appraisal-tools.html>.
- [33] M. Karamali, Z. Asemi, M. Ahmadi-Dastjerdi, A. Esmailzadeh, Calcium plus vitamin D supplementation affects pregnancy outcomes in gestational diabetes: randomized, double-blind, placebo-controlled trial, *Publ. Health Nutr.* 19 (1) (2016) 156–163.
- [34] M. Jamilian, M. Karamali, M. Taghizadeh, N. Sharifi, Z. Jafari, M.R. Memarzadeh, M. Mahlouji, Z. Asemi, Vitamin D and evening primrose oil administration improve glycemia and lipid profiles in women with gestational diabetes, *Lipids* 51 (3) (2016) 349–356.
- [35] M. Jamilian, M. Samimi, F.A. Ebrahimi, T. Hashemi, M. Taghizadeh, M. Razavi, M. Sanami, Z. Asemi, The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes, *J. Clin. Lipidol.* 11 (2) (2017) 459–468.
- [36] Z. Asemi, T. Hashemi, M. Karamali, M. Samimi, A. Esmailzadeh, Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial-3, *Am. J. Clin. Nutr.* 98 (6) (2013) 1425–1432.
- [37] Z. Asemi, M. Karamali, A. Esmailzadeh, Favorable effects of vitamin D supplementation on pregnancy outcomes in gestational diabetes: a double blind randomized controlled clinical trial, *Horm. Metab. Res.* 47 (8) (2015) 565–570.
- [38] Z. Asemi, M. Karamali, A. Esmailzadeh, Effects of calcium-vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial, *Diabetologia* 57 (9) (2014) 1798–1806.
- [39] S. Shahgheibi, F. Farhadifar, B. Pouya, The effect of vitamin D supplementation on gestational diabetes in high-risk women: results from a randomized placebo-

- controlled trial, *J. Res. Med. Sci.* 21 (2016) 2.
- [40] H. Mozaffari-Khosravi, M. Hosseinzadeh-Shamsi-Anar, M.A. Salami, H. Hadinedoushan, M. Mozayan, Effects of a single post-partum injection of a high dose of vitamin D on glucose tolerance and insulin resistance in mothers with first-time gestational diabetes mellitus, *Diabet. Med.* 29 (1) (2012) 36–42.
  - [41] M. Mojibian, S. Soheilykhah, M.A.F. Zadeh, M.J. Moghadam, The effects of vitamin D supplementation on maternal and neonatal outcome: a randomized clinical trial, *Iran. J. Reproductive Med.* 13 (11) (2015) 687.
  - [42] M. Hosseinzadeh-Shamsi-Anar, H. Mozaffari-Khosravi, M.-A. Salami, H. Hadinedoushan, M.R. Mozayan, The efficacy and safety of a high dose of vitamin D in mothers with gestational diabetes mellitus: a randomized controlled clinical trial, *Iran. J. Med. Sci.* 37 (3) (2012) 159.
  - [43] M. Valizadeh, Z. Piri, F. Mohammadian, K. Kamali, H.R.A. Moghadami, The impact of vitamin D supplementation on post-partum glucose tolerance and insulin resistance in gestational diabetes: a randomized controlled trial, *Int. J. Endocrinol. Metabol.* 14 (2) (2016).
  - [44] R. Yazdchi, B.P. Gargari, M. Asghari-Jafarabadi, F. Sahhaf, Effects of vitamin D supplementation on metabolic indices and hs-CRP levels in gestational diabetes mellitus patients: a randomized, double-blinded, placebo-controlled clinical trial, *Nutr. Res. Pract.* 10 (3) (2016) 328–335.
  - [45] H.G. Tehrani, F. Mostajeran, B. Banihashemi, Effect of vitamin D supplementation on the incidence of gestational diabetes, *Adv. Biomed. Res.* 6 (2017) 79.
  - [46] S. Mohammadian, N. Fatahi, H. Zaeri, M.A. Vakili, Effect of vitamin D3 supplement in glycemic control of pediatrics with type 1 diabetes mellitus and vitamin D deficiency, *J. Clin. Diagn. Res.* 9 (3) (2015) Sc05–7.
  - [47] A. Ataie-Jafari, A.B. Rahmat, F. Abbasi, S.C. Loke, M. Qorbani, B. Larijani, Vitamin D status and associated factors in recent-onset type 1 diabetic children in Iran, *J. Diabetes Metab. Disord.* 11 (1) (2012) 12.
  - [48] M. Ordoeei, A. Shojoadiny-Ardekani, S.H. Hoseiniipoor, M. Miroliahi, H. Zare-Zardini, Effect of vitamin D on HbA1c levels of children and adolescents with diabetes mellitus type 1, *Minerva Pediatr.* 69 (5) (2017) 391–395.
  - [49] A. Taleai, M. Mohamadi, Z. Adgi, The effect of vitamin D on insulin resistance in patients with type 2 diabetes, *Diabetol. Metab. Syndrome* 5 (1) (2013) 8.
  - [50] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, M.R. Eshraghian, A. Houshiarrad, A. Gharavi, A. Kalayi, N. Shariatzadeh, M. Zahedirad, N. Khalaji, H. Haidari, Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial, *BMC Med.* 9 (2011) 125.
  - [51] R. Heshmat, O. Tabatabaei-Malazy, S. Abbaszadeh-Ahranjani, S. Shahbazi, G. Khooshehchin, F. Bandarian, B. Larijani, Effect of vitamin D on insulin resistance and anthropometric parameters in Type 2 diabetes: a randomized double-blind clinical trial, *Daru* 20 (1) (2012) 10.
  - [52] B. Nikooyeh, T.R. Neyestani, M. Farvid, H. Alavi-Majd, A. Houshiarrad, A. Kalayi, N. Shariatzadeh, A.A. Gharavi, S. Heravifard, N. Tayebinejad, Daily consumption of vitamin D-or vitamin D+ calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial, *Am. J. Clin. Nutr.* 93 (4) (2011) 764–771.
  - [53] E. Shaseb, M. Tohidi, M. Abbasnazari, D. Khalili, A. Talasaz, H. Omrani, F. Hadaegh, The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial, *Acta Diabetol.* 53 (4) (2016) 575–582.
  - [54] S. Heravifard, T.R. Neyestani, B. Nikooyeh, H. Alavi-Majd, A. Houshiarrad, A. Kalayi, N. Shariatzadeh, M. Zahedirad, N. Tayebinejad, S. Salekzamani, Regular consumption of both vitamin D-and calcium-and vitamin D-fortified yogurt drink is equally accompanied by lowered blood lipoprotein (a) and elevated apoprotein A1 in subjects with type 2 diabetes: a randomized clinical trial, *J. Am. Coll. Nutr.* 32 (1) (2013) 26–30.
  - [55] N. Baziar, K. Jafarian, Z. Shadman, M. Qorbani, M.K. Nikoo, M.A. Mishani, Effect of therapeutic dose of vitamin D on serum adiponectin and glycemia in vitamin D-insufficient or deficient type 2 diabetic patients, *Iran. Red Crescent Med. J.* 16 (9) (2014).
  - [56] T.R. Neyestani, B. Nikooyeh, H. Alavi-Majd, N. Shariatzadeh, A. Kalayi, N. Tayebinejad, S. Heravifard, S. Salekzamani, M. Zahedirad, Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes, *J. Clin. Endocrinol. Metab.* 97 (6) (2012) 2005–2011.
  - [57] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, M.R. Eshraghian, A. Houshiarrad, A. Kalayi, N. Shariatzadeh, N. Khalaji, Improvement of vitamin D status resulted in amelioration of biomarkers of systemic inflammation in the subjects with type 2 diabetes, *Diabetes/Metabol. Res. Rev.* 28 (5) (2012) 424–430.
  - [58] M. Hajimohammadi, S. Shab-Bidar, T.R. Neyestani, Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial, *Eur. J. Nutr.* 56 (6) (2017) 2029–2036.
  - [59] B. Nikooyeh, T. Neyestani, N. Tayebinejad, H. Alavi-Majd, N. Shariatzadeh, A. Kalayi, M. Zahedirad, S. Heravifard, S. Salekzamani, Daily intake of vitamin D-or calcium-vitamin D-fortified Persian yogurt drink (doogh) attenuates diabetes-induced oxidative stress: evidence for antioxidative properties of vitamin D, *J. Hum. Nutr. Diet.* 27 (s2) (2014) 276–283.
  - [60] E.Y. Rad, M. Djalali, F. Koohdani, A.A. Saboor-Yaraghi, M.R. Eshraghian, M.H. Javanbakht, S. Saboori, M. Zarei, M.J. Hosseinzadeh-Attar, The effects of vitamin D supplementation on glucose control and insulin resistance in patients with diabetes type 2: a randomized clinical trial study, *Iran. J. Public Health* 43 (12) (2014) 1651.
  - [61] S. Shab-Bidar, T. Neyestani, A. Djazayeri, The interactive effect of improvement of vitamin D status and VDR FokI variants on oxidative stress in type 2 diabetic subjects: a randomized controlled trial, *Eur. J. Clin. Nutr.* 69 (2) (2015) 216–222.
  - [62] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, Vitamin D receptor Cdx-2-dependent response of central obesity to vitamin D intake in the subjects with type 2 diabetes: a randomised clinical trial, *Br. J. Nutr.* 114 (9) (2015) 1375–1384.
  - [63] S. Bonakdaran, A.F. Nejad, V. Abdol-Reza, A. Hatefi, M. Shakeri, Impact of oral 1,25-dihydroxy vitamin D (calcitriol) replacement therapy on coronary artery risk factors in type 2 diabetic patients, *Endocr. Metab. Immune Disord. - Drug Targets* 13 (4) (2013) 295–300.
  - [64] S. Ghavamzadeh, M. Mobasser, R. Mahdavi, The effect of vitamin D supplementation on adiposity, blood glycated hemoglobin, serum leptin and tumor necrosis factor- $\alpha$  in type 2 diabetic patients, *Int. J. Prev. Med.* 5 (9) (2014) 1091.
  - [65] M.H. Eftekhari, M. Akbarzadeh, M.H. Dabbaghmanesh, J. Hasanazadeh, Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients, *Asia Pac. J. Clin. Nutr.* 20 (4) (2011) 521–526.
  - [66] M.H. Eftekhari, M. Akbarzadeh, M.H. Dabbaghmanesh, J. Hasanazadeh, The effect of calcitriol on lipid profile and oxidative stress in hyperlipidemic patients with type 2 diabetes mellitus, *ARYA Atheroscler.* 10 (2) (2014) 82–88.
  - [67] M. Vahedian, M.R. Maracy, M. Parham, Impact of vitamin D on insulin resistance in patients with type II diabetes: a comprehensive cohort design, *J. Isfahan Med. School* 31 (239) (2013) 777–791.
  - [68] Z. Asemi, F. Raygan, F. Bahmani, Z. Rezavandi, H.R. Talari, M. Rafiee, S. Poladchang, M.D. Mofrad, S. Taheri, A.A. Mohammadi, The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD, *Br. J. Nutr.* 116 (2) (2016) 286–293.
  - [69] A. Farrokhan, F. Raygan, F. Bahmani, H.R. Talari, R. Esfandiari, A. Esmailzadeh, Z. Asemi, Long-term vitamin D supplementation affects metabolic status in vitamin D-deficient type 2 diabetic patients with coronary artery disease, *J. Nutr.* 147 (3) (2017) 384–389.
  - [70] N. Ahmadi, M. Mortazavi, B. Iraj, G. Askari, Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? *J. Res. Med. Sci.: the official journal of Isfahan University of Medical Sciences* 18 (5) (2013) 374.
  - [71] M. Tabesh, L. Azadbakht, E. Faghihimani, M. Tabesh, A. Esmailzadeh, Effects of calcium plus vitamin D supplementation on anthropometric measurements and blood pressure in vitamin D insufficient people with type 2 diabetes: a randomized controlled clinical trial, *J. Am. Coll. Nutr.* 34 (4) (2015) 281–289.
  - [72] M. Tabesh, L. Azadbakht, E. Faghihimani, M. Tabesh, A. Esmailzadeh, Effects of calcium-vitamin D co-supplementation on metabolic profiles in vitamin D insufficient people with type 2 diabetes: a randomised controlled clinical trial, *Diabetologia* 57 (10) (2014) 2038–2047.
  - [73] M. Tabesh, L. Azadbakht, E. Faghihimani, M. Tabesh, A. Esmailzadeh, Calcium-vitamin D cosupplementation influences circulating inflammatory biomarkers and adipocytokines in vitamin D-insufficient diabetics: a randomized controlled clinical trial, *J. Clin. Endocrinol. Metab.* 99 (12) (2014) E2485–E2493.
  - [74] N. Rahimi, M.A.S. Sharif, A.R. Goharian, A.H. Pour, The effects of aerobic exercises and 25 (OH) D supplementation on GLP1 and DPP4 level in Type II diabetic patients, *Int. J. Prev. Med.* 8 (2017).
  - [75] M. Nadi, S.M. Marandi, F. Esfarjani, M. Saleki, M. Mohammadi, The comparison between effects of 12 weeks combined training and vitamin D supplement on improvement of sensory-motor neuropathy in type 2 diabetic women, *Adv. Biomed. Res.* 6 (2017) 55.
  - [76] S.M. Mohammadi, S.A. Eghbali, S. Soheilykhah, S.J. Ashkezari, M. Salami, M. Afkhami-Ardekani, A. Afkhami-Ardekani, The effects of vitamin D supplementation on adiponectin level and insulin resistance in first-degree relatives of subjects with type 2 diabetes: a randomized double-blinded controlled trial, *Electron. Physician* 8 (9) (2016) 2849–2854.
  - [77] H. Nasri, S. Behradmanesh, A. Ahmadi, M. Rafieian-Kopaei, Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients: a randomized, double-blind, placebo controlled clinical trial, *J. Nephropathol* 3 (1) (2014) 29–33.
  - [78] H. Nasri, S. Behradmanesh, A.R. Maghsoudi, A. Ahmadi, P. Nasri, M. Rafieian-Kopaei, Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus: a randomized double blind clinical trial, *J. Ren. Inj. Prev.* 3 (1) (2014) 31–34.
  - [79] A. Momeni, M. Mirhosseini, M. Kabiri, S. Kheiri, Effect of vitamin D on proteinuria in type 2 diabetic patients, *J. Nephropathol* 6 (1) (2017) 10–14.
  - [80] S. Soheilykhah, M. Mojibian, M. Rashidi, S. Rahimi-Saghand, F. Jafari, Maternal vitamin D status in gestational diabetes mellitus, *Nutr. Clin. Pract.* 25 (5) (2010) 524–527.
  - [81] L. Jafarzadeh, A. Motamedi, M. Behradmanesh, R. Hashemi, A comparison of serum levels of 25-hydroxy vitamin D in pregnant women at risk for gestational diabetes mellitus and women without risk factors, *Mater. Sociomed.* 27 (5) (2015) 318–322.
  - [82] F. Haidari, M.-T. Jalali, N. Shahbazian, M.-H. Haghighizadeh, E. Azadegan, Comparison of serum levels of vitamin D and inflammatory markers between women with gestational diabetes mellitus and healthy pregnant control, *J. Fam. Reprod. Health* 10 (1) (2016) 1.
  - [83] A. Vosoughi, A. Aliasgarzadeh, A. Bahrami, F. Abbasalizadeh, M. Niafar, F. Najafipour, N. Aghamohammadzadeh, Z. Nikniaz, Concentration of maternal serum 25-hydroxy Vitamin D and gestational 2 diabetes mellitus risk, *Pharmaceut. Sci.* 23 (3) (2017) 189–192.
  - [84] S. Aslani, A. Hossein-Nezhad, K. Mirzaei, Z. Maghbooli, A.N. Afshar, F. Karimi, VDR FokI polymorphism and its potential role in the pathogenesis of gestational diabetes mellitus and its complications, *Gynecol. Endocrinol.* 27 (12) (2011) 1055–1060.

- [85] F. Saki, G.R. Omrani, Y. Pouralborz, M.H. Dabbaghmanesh, Vitamin D deficiency and the associated factors in children with type 1 diabetes mellitus in southern Iran, *Int. J. Diabetes Dev. Ctries.* 37 (1) (2017) 78–84.
- [86] A. Saedisomeolia, E. Taheri, M. Djalali, A.M. Moghadam, M. Qorbani, Association between serum level of vitamin D and lipid profiles in type 2 diabetic patients in Iran, *J. Diabetes Metab. Disord.* 13 (1) (2014) 7.
- [87] M. Afarideh, P. Ghanbari, S. Noshad, A. Ghajar, M. Nakhjavani, A. Esteghamati, Raised serum 25-hydroxyvitamin D levels in patients with active diabetic foot ulcers, *Br. J. Nutr.* 115 (11) (2016) 1938–1946.
- [88] A. Saedisomeolia, E. Taheri, M. Djalali, A. Djazayeri, M. Qorbani, A. Rajab, B. Larjani, Vitamin D status and its association with antioxidant profiles in diabetic patients: a cross-sectional study in Iran, *Indian J. Med. Sci.* 67 (1–2) (2013) 29–37.
- [89] M. Djalali, E. Taheri, A. Saedisomeolia, A. Djazayeri, A. Rahemi, M. Hashemi, B. Larjani, Vitamin D status of type 2 diabetic patients compared with healthy subjects in the Islamic Republic of Iran, *East. Mediterr. Health J.* 19 (SUPPL.2) (2013).
- [90] S. Bonakdaran, N. Shoeibi, Is there any correlation between vitamin D insufficiency and diabetic retinopathy? *Int. J. Ophthalmol.* 8 (2) (2015) 326–331.
- [91] S. Bonakdaran, M. Hami, A. Hatefi, The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus, *Saudi J. Kidney Dis Transpl* 23 (6) (2012) 1215–1220.
- [92] S. Bonakdaran, A.R. Varasteh, Correlation between serum 25 hydroxy vitamin D3 and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients, *Saudi Med. J.* 30 (4) (2009) 509–514.
- [93] F. Haidari, M. Zakerkish, M. Karandish, A. Saki, S. Pooraziz, Association between serum Vitamin D level and glycemic and inflammatory markers in non-obese patients with type 2 diabetes, *Iran. J. Med. Sci.* 41 (5) (2016) 367.
- [94] F. Sharifi, A. Ziaee, R. Sayari, N. Mousavinasab, S. Oveisi, Insulin resistance and its relationship with serum Vitamin D concentrations in offspring of patients with type 2 diabetes, *HealthMED* (1782) 1782.
- [95] H. Nasri, M. Rafieian-Kopaei, Significant difference of serum 25-hydroxyvitamin D level in male hemodialysis patients with or without diabetes; a single center study, *J. Nephropharmacol.* 1 (2) (2012) 15–16.
- [96] G. Rahmamezad, F.J. Mashayekhi, M.T. Goodarzi, M.R. Rezvanfar, A. Sadeghi, Association between vitamin D receptor ApaI and TaqI gene polymorphisms and gestational diabetes mellitus in an Iranian pregnant women population, *Gene* 581 (1) (2016) 43–47.
- [97] Z. Mohammadnejad, M. Ghanbari, R. Ganjali, J.T. Afshari, M. Heydarpour, S.M. Taghavi, S. Fatemi, H. Rafatpanah, Association between vitamin D receptor gene polymorphisms and type 1 diabetes mellitus in Iranian population, *Mol. Biol. Rep.* 39 (2) (2012) 831–837.
- [98] S. Bonakdaran, M. Abbaszadegan, E. Dadkhah, M. Khajeh-Dalouie, Vitamin D receptor gene polymorphisms in type 1 diabetes mellitus: a new pattern from Khorasan province, Islamic Republic of Iran/Polymorphismes du gene du recepteur de la vitamine D et diabete de type 1: un nouveau modele dans la province de Khorasan (Republique islamique d'Iran), *East. Mediterr. Health J.* 18 (6) (2012) 614.
- [99] Z. Ghandchi, T. Neyestani, A.A. Saboor Yaraghi, M.R. Eshraghian, A. Gharavi, N. Shariatzadeh, A. Kalayi, A. Houshiarrad, Vitamin D status and the predictors of circulating T helper 1-type immunoglobulin levels in Iranian subjects with type 1 diabetes and their siblings: a case-control study, *J. Hum. Nutr. Diet.* 25 (4) (2012) 365–372.
- [100] M. Tohidi, M. Bozorgmanesh, R. Mohebi, D. Khalili, N. Saadat, N. Khorrami, F. Azizi, F. Hadaegh, Non-linear association between 25-hydroxyvitamin D and the incidence of Type 2 diabetes: a community-based nested case-control study, *Diabet. Med.* 30 (8) (2013) 934–938.
- [101] A. Esteghamati, Z. Aryan, A. Esteghamati, M. Nakhjavani, Vitamin D deficiency is associated with insulin resistance in nondiabetics and reduced insulin production in type 2 diabetics, *Horm. Metab. Res.* 47 (4) (2015) 273–279.
- [102] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, Vitamin D receptor gene polymorphisms, metabolic syndrome, and type 2 diabetes in Iranian subjects: No association with observed SNPs, *Int. J. Vitam. Nutr. Res.* (2017) 1–10.
- [103] R. Nosratabadi, M.K. Arababadi, V.A. Salehabad, Vitamin D receptor polymorphisms in type 2 diabetes in southeastern Iranian patients, *Lab. Med.* 42 (1) (2015) 32–34.
- [104] M.A. Bayani, R. Ghadimi, R. Akbari, F. Saeedi, B. Banasaz, Status of Vitamin-D in diabetic patients, *Caspian J. Int. Med.* 5 (1) (2014) 40–42.
- [105] Z. Heidari, M.A. Mashhadi, T. Nakhaei, Investigation of vitamin D serum level in patients with type 2 diabetes in comparison with control group, *Der Pharm. Lett.* 8 (11) (2016) 177–181.
- [106] A. Hossein-Nezhad, Z. Maghbooli, A.-R. Vassigh, B. Larjani, Prevalence of gestational diabetes mellitus and pregnancy outcomes in Iranian women, *Taiwan. J. Obstet. Gynecol.* 46 (3) (2007) 236–241.
- [107] J. Harreiter, G. Dovjak, A. Kautzky-Willer, Gestational diabetes mellitus and cardiovascular risk after pregnancy, *Women's Health* 10 (1) (2014) 91–108.
- [108] M. Alzaim, R.J. Wood, Vitamin D and gestational diabetes mellitus, *Nutr. Rev.* 71 (3) (2013) 158–167.
- [109] International Diabetes Federation. Diabetes: facts and figures. IDF, [www.idf.org/worlddiabetesday/toolkit/gp/facts-figures](http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures) (2014).
- [110] H. Nasri, S. Behradmanesh, A.R. Maghsoudi, A. Ahmadi, P. Nasri, M. Rafieian-Kopaei, Efficacy of supplementary vitamin D on improvement of glycemic parameters in patients with type 2 diabetes mellitus; a randomized double blind clinical trial, *J. Ren. Inj. Prev.* 3 (1) (2014) 31.
- [111] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, M.-R. Eshraghian, A. Houshiarrad, A.a. Gharavi, A. Kalayi, N. Shariatzadeh, M. Zahedirad, N. Khalaji, Regular consumption of vitamin D-fortified yogurt drink (Doogh) improved endothelial biomarkers in subjects with type 2 diabetes: a randomized double-blind clinical trial, *BMC Med.* 9 (1) (2011) 125.
- [112] M. Hajimohammadi, S. Shab-Bidar, T.R. Neyestani, Consumption of vitamin D-fortified yogurt drink increased leptin and ghrelin levels but reduced leptin to ghrelin ratio in type 2 diabetes patients: a single blind randomized controlled trial, *Eur. J. Nutr.* (2017) 1–8.
- [113] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, Vitamin D receptor Cdx-2-dependent response of central obesity to vitamin D intake in the subjects with type 2 diabetes: a randomised clinical trial, *Br. J. Nutr.* 114 (9) (2015) 1375–1384.
- [114] M.H. Eftekhari, M. Akbarzadeh, M.H. Dabbaghmanesh, J. Hasanazadeh, Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients, *Asia Pac. J. Clin. Nutr.* 20 (4) (2011) 521–526.
- [115] T. Jafari, E. Faghihimani, A. Feizi, B. Iraj, S.H. Javanmard, A. Esmaillzadeh, A.A. Fallah, G. Askari, Effects of vitamin D-fortified low fat yogurt on glycemic status, anthropometric indexes, inflammation, and bone turnover in diabetic postmenopausal women: a randomised controlled clinical trial, *Clin. Nutr.* 35 (1) (2016) 67–76.
- [116] A. Talaei, M. Mohamadi, Z. Adgi, The effect of vitamin D on insulin resistance in patients with type 2 diabetes, *Diabetol. Metab. Syndrome* 5 (1) (2013) 8.
- [117] S.M. Mohammadi, S.A. Eghbali, S. Soheilikhah, S.J. Ashkezari, M. Salami, M. Afkhami-Ardekani, A. Afkhami-Ardekani, The effects of vitamin D supplementation on adiponectin level and insulin resistance in first-degree relatives of subjects with type 2 diabetes: a randomized double-blinded controlled trial, *Electron. Physician* 8 (9) (2016) 2849.
- [118] S.A. Hoseini, A. Aminorroaya, B. Iraj, M. Amini, The effects of oral vitamin D on insulin resistance in pre-diabetic patients, *J. Res. Med. Sci.* 18 (1) (2013) 47–51.
- [119] L. O'Mahony, M. Ctepien, M.J. Gibney, A.P. Nugent, L. Brennan, The potential role of vitamin D enhanced foods in improving vitamin D status, *Nutrients* 3 (12) (2011) 1023–1041.
- [120] S. Shab-Bidar, T.R. Neyestani, A. Djazayeri, Efficacy of vitamin D3-fortified-yogurt drink on anthropometric, metabolic, inflammatory and oxidative stress biomarkers according to vitamin D receptor gene polymorphisms in type 2 diabetic patients: a study protocol for a randomized controlled clinical trial, *BMC Endocr. Disord.* 11 (2011) 12.
- [121] A. Alamdari, R. Mozafari, A. Tafakhori, S. Faghihi-Kashani, N. Hafezi-Nejad, S. Sheikhabaei, N. Naderi, M. Ebadi, A. Esteghamati, An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects, *Neurol. Sci.* 36 (7) (2015) 1121–1126.
- [122] A. Esteghamati, A. Fotouhi, S. Faghihi-Kashani, N. Hafezi-Nejad, B. Heidari, S. Sheikhabaei, A. Zandieh, M. Nakhjavani, Non-linear contribution of serum vitamin D to symptomatic diabetic neuropathy: a case-control study, *Diabetes Res. Clin. Pract.* 111 (2016) 44–50.
- [123] R. Razzaghi, H. Pourbagheri, M. Momen-Heravi, F. Bahmani, J. Shadi, Z. Soleimani, Z. Asemi, The effects of vitamin D supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial, *J. Diabet. Complicat.* 31 (4) (2017) 766–772.